{'fraction_non_alphanumeric': 0.010126582278481013, 'fraction_numerical': 0.0012658227848101266, 'mean_word_length': 5.228346456692913, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Protecting patient access to oral cancer drugs in the United States.

In Journal of Oncology Practice, Han et al1 report on the experiences of Canadian oncologists and hematologists in confronting barriers to access for oral cancer drugs. The experience with oral cancer drugs in the United States is shaped by a number of distinguishing circumstances, including a multipayer insurance system that relies on a mix of public and private sector coverage, the role of state and federal policymakers in establishing patient safeguards for both public and private health insurance, and the degree of regulation and scrutiny focused on the actions of health care professionals. This commentary provides an update on developments in the United States regarding patient access to oral cancer drugs.